R&D channel feed

Al­ny­lam, Roche’s RNAi can­di­date scores mid-stage win in hy­per­ten­sion

3 weeks ago

Val­ne­va and Pfiz­er tout re­sults for the PhII of its Ly­me dis­ease vac­cine

3 weeks ago

CymaBay meets pri­ma­ry, key sec­ondary end­points in PhI­II liv­er tri­al

3 weeks ago

J&J shut­ters PhI­II tri­al for pul­monary hy­per­ten­sion drug, block­ing its ex­pand­ed use as patent ex­piry looms

3 weeks ago
Pharma

Astel­las pulls law­suit over price ne­go­ti­a­tions as Xtan­di side­steps first list of 10 drugs

3 weeks ago

Janssen looks to turn PhI­II win for Ry­bre­vant in EGFR-mu­tat­ed NSCLC in­to pres­sure on As­traZeneca block­buster

3 weeks ago
Pharma

Bio­gen names Jane Gro­gan head of re­search af­ter split­ting R&D

3 weeks ago
People

Mod­er­na touts broad­er an­ti­body da­ta on up­dat­ed Covid vac­cine as it gears up for fall roll­out

3 weeks ago
Coronavirus

Bio­Car­dia un­veils in­ter­im da­ta that led it to stop PhI­II en­roll­ment of heart fail­ure stem cell ther­a­py

3 weeks ago
Cell/Gene Tx

Ole­ma On­col­o­gy re­ceives $180M in to­tal fund­ing

3 weeks ago
Financing

Tiv­dak gets pri­ma­ry end­point in PhI­II con­fir­ma­to­ry study

3 weeks ago

Beam dos­es first pa­tient with base-edit­ed cell ther­a­py

3 weeks ago
Cell/Gene Tx

First RNA edit­ing ther­a­py nears clin­ic, as Wave ask reg­u­la­tors to green­light hu­man tests

3 weeks ago

Bay­er ex­pands Keren­dia heart fail­ure pro­gram to 15,000 pa­tients as it plans to start three Phase III tri­als

4 weeks ago
Pharma

Roche says Ale­cen­sa helps keep ALK-pos­i­tive lung can­cer at bay af­ter surgery as it looks to ex­pand la­bel

4 weeks ago

BioN­Tech, Du­al­i­ty­Bio steer ADC in­to PhI­II, with aim to com­pete in HER2-low sub­group with En­her­tu

4 weeks ago

Bavar­i­an Nordic aban­dons Covid boost­er af­ter da­ta show it's not as ef­fec­tive against new vari­ants

4 weeks ago
Coronavirus

Zevra beefs up rare dis­ease port­fo­lio via $91M ac­qui­si­tion of Ac­er Ther­a­peu­tics

4 weeks ago
Deals

As Revlim­id sales fall, Bris­tol My­ers turns to its next mul­ti­ple myelo­ma pill that's a mol­e­c­u­lar glue

4 weeks ago

Sage shrinks work­force by 40% in light of ma­jor de­pres­sion drug re­jec­tion 

4 weeks ago
People

FDA+ roundup: FDA is­sues fi­nal guid­ance on use of re­al-world ev­i­dence

4 weeks ago
Pharma
FDA+

Af­ter de­lay, Abeona aims for fall FDA sub­mis­sion for rare skin con­di­tion cell ther­a­py

4 weeks ago
FDA+

PhI­II fail in Duchenne casts shad­ow over Fi­bro­Gen's top an­ti-fi­brot­ic pro­gram

4 weeks ago

Ex­clu­sive: 10x Ge­nomics CEO touts ‘in­cred­i­ble trac­tion’ with newest launch, ship­ping over 100 spa­tial bi­ol­o­gy an­a­lyz­ers

4 weeks ago
First page Previous page 123456 Next page Last page
A service from the Financial Times